Literature DB >> 15447630

Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Isaac M Westwood1, Simon J Holton, Fernando Rodrigues-Lima, Jean-Marie Dupret, Sanjib Bhakta, Martin E M Noble, Edith Sim.   

Abstract

The gene for NAT (arylamine N-acetyltransferase) from Pseudomonas aeruginosa (panat) has been cloned from genomic DNA, and the gene product (PANAT) expressed as an N-terminal histidine-tagged protein in Escherichia coli and purified via nickel ion affinity chromatography. The specific activities of PANAT against a broad range of substrates have been investigated and compared with those of other prokaryotic NAT enzymes. For most arylamine substrates identified, PANAT exhibits in vitro specific activities typically one order of magnitude greater than those of recombinant NAT enzymes from Mycobacterium smegmatis or Salmonella typhimurium. Among the substrates of PANAT so far identified are the anti-tubercular drug isoniazid, 5-aminosalicylate (a drug used in the treatment of inflammatory bowel disease), as well as important environmental pollutants such as 3,4-dichloroaniline and 2-aminofluorene. As well as acetylating common NAT substrates, PANAT is unique among the prokaryotic NATs so far studied in acetylating the folate precursor 4-aminobenzoic acid and the folate catabolite 4-aminobenzoylglutamate. The recombinant protein has been expressed in sufficient quantity to allow protein crystallization, and we have subsequently determined the 1.95 A structure of PANAT by X-ray crystallography.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15447630      PMCID: PMC1134735          DOI: 10.1042/BJ20041330

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

Review 2.  N-acetyltransferase.

Authors:  D A Evans
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

3.  Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium.

Authors:  J C Sinclair; R Delgoda; M E Noble; S Jarmin; N K Goh; E Sim
Journal:  Protein Expr Purif       Date:  1998-04       Impact factor: 1.650

4.  Trends in drug-resistant tuberculosis in the United States, 1993-1996.

Authors:  M Moore; I M Onorato; E McCray; K G Castro
Journal:  JAMA       Date:  1997-09-10       Impact factor: 56.272

5.  Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate.

Authors:  B Riddle; W P Jencks
Journal:  J Biol Chem       Date:  1971-05-25       Impact factor: 5.157

6.  Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.

Authors:  H Carsenti-Etesse; J D Cavallo; P M Roger; I Ziha-Zarifi; P Plesiat; E Garrabé; P Dellamonica
Journal:  Clin Microbiol Infect       Date:  2001-03       Impact factor: 8.067

7.  Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis.

Authors:  M Payton; C Gifford; P Schartau; C Hagemeier; A Mushtaq; S Lucas; K Pinter; E Sim
Journal:  Microbiology       Date:  2001-12       Impact factor: 2.777

8.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

Review 9.  Side effects of corticosteroid therapy.

Authors:  A L Buchman
Journal:  J Clin Gastroenterol       Date:  2001-10       Impact factor: 3.062

10.  Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target.

Authors:  Sanjib Bhakta; Gurdyal S Besra; Anna M Upton; Tanya Parish; Carolyn Sholto-Douglas-Vernon; Kevin J C Gibson; Stuart Knutton; Siamon Gordon; Rosangela P DaSilva; Matthew C Anderton; Edith Sim
Journal:  J Exp Med       Date:  2004-04-26       Impact factor: 14.307

View more
  24 in total

1.  Insights into the phylogeny or arylamine N-acetyltransferases in fungi.

Authors:  Marta Martins; Julien Dairou; Fernando Rodrigues-Lima; Jean-Marie Dupret; Philippe Silar
Journal:  J Mol Evol       Date:  2010-07-31       Impact factor: 2.395

2.  Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.

Authors:  Elizabeth Fullam; Akane Kawamura; Helen Wilkinson; Areej Abuhammad; Isaac Westwood; Edith Sim
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

Review 3.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

4.  Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function.

Authors:  Jason M Walraven; John O Trent; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-03-19       Impact factor: 3.922

5.  Structure of Mesorhizobium loti arylamine N-acetyltransferase 1.

Authors:  Simon J Holton; Julien Dairou; James Sandy; Fernando Rodrigues-Lima; Jean Marie Dupret; Martin E M Noble; Edith Sim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2004-12-24

6.  Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.

Authors:  James Sandy; Adeel Mushtaq; Simon J Holton; Pamela Schartau; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

7.  Mycobacterium tuberculosis Arylamine N-Acetyltransferase Acetylates and Thus Inactivates para-Aminosalicylic Acid.

Authors:  Xude Wang; Shanshan Yang; Jing Gu; Jiaoyu Deng
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 8.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

9.  Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis.

Authors:  Benjamin Pluvinage; Inés Li de la Sierra-Gallay; Marta Martins; Nilusha Ragunathan; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-09-19

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.